Pedro de Noronha Pissarra

CEO at Chrysea Limited

Speaker

Pedro is an established, highly-networked and seasoned life-sciences entrepreneur, with over 29-years track record in the biotechnology and healthcare industry.

A graduate from Kings College London he carried out research at Massachusetts Institute of Technology (MIT), the Technical University of Denmark (DTU), and Técnico Lisbon (IST); He further took a 12-months Masters Programme in Management at the University of Texas, Austin. He Founded in 1996 and sold in 2018 the Biotecnol Group of companies, RDN (biopharmaceutical products CDMO company sold to the Iberfar Group) and Biotecnol Limited (a pioneering immuno-oncology company, Sold to Chiome, Inc). Pedro was a Board Member of Vida Rhein SA, part of the Rhein Biotech NV group, developing hepatitis vaccines (sold to Dynavax, Inc) and Board Member of 4Tune Engineering, a Portuguese leading data-analytics and risk-analysis company, a pioneering leader in Biomanufacturing 4.0 (sold to Valgenesis, Inc). With a sizeable deal-flow in financing and transactions, including fund-raising, licensing deal-making, M&A, cross-border. Pedro brings a wealth of experience from an entrepreneurial and leadership perspective across the various components of a biotech company value-chain, including a proven track record in various fields ranging from the development of biosimilars, immune-check point modulators, T-cell engagers, to biomanufacturing operations, regulatory and clinical development.

Pedro has collected over the years numerous awards for his pioneering achievements in bioentrepreneurship and life-sciences.